BioNTech (NASDAQ:BNTX) Trading 2% Higher – Time to Buy?

BioNTech SE (NASDAQ:BNTX) shares shot up 2% on Monday . The stock traded as high as $115.98 and last traded at $115.39. 290,685 shares were traded during trading, a decline of 64% from the average session volume of 810,922 shares. The stock had previously closed at $113.13.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BNTX. Berenberg Bank began coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and raised their price target for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Finally, Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $138.79.

BioNTech Stock Performance

The company’s fifty day simple moving average is $113.60 and its two-hundred day simple moving average is $97.80. The company has a market capitalization of $28.95 billion, a price-to-earnings ratio of -54.95 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. Equities research analysts predict that BioNTech SE will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares during the period. Planning Capital Management Corp lifted its position in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. Blue Trust Inc. boosted its stake in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the period. Finally, Daiwa Securities Group Inc. grew its position in BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.